All In Biotech

NDA 022186 · Long Grove Pharms

Ak-Fluor 25%

Fluorescein Sodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Aug 8, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

106

19 Phase 3, 6 recruiting

FAERS reports

240

197 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 26, 2026.

AK-FLUOR ® 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. AK-FLUOR is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. ( 1 )

Mechanism: Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AK-FLUOR 25% · FLUORESCEIN SODIUM EQ 500MG BASE/2ML (EQ 250MG BASE/ML) · INJECTABLE, INTRAVENOUS · Discontinued · TE AP
  • AK-FLUOR 10% · FLUORESCEIN SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorescein" as an intervention, any sponsor and status, largest first.

All 106 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual acuity reduced31
  • nausea25
  • urticaria16
  • anaphylactic reaction15
  • headache15
  • pruritus15
  • dizziness13
  • drug hypersensitivity13
  • vomiting13
  • dyspnoea12
  • retinal haemorrhage12
  • hyperhidrosis10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200512
20065
20071
20085
200934
20104
20112
20125
20132
20149
201514
201626
201723
201814
201915
202012
20217
20229
20236
202412
20256
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,795 on PubMed

Sponsor: Long Grove Pharms · Also marketed as Ak-Fluor 10%

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.